等待開盤 01-29 09:30:00 美东时间
-0.610
-0.66%
今日重点评级关注:Guggenheim:维持MBX Biosciences"买入"评级,目标价从77美元升至88美元;摩根士丹利:维持DraftKings"超配"评级,目标价从50美元升至53美元
01-20 10:26
Needham analyst Kyle Peterson reiterates Axos Financial (NYSE:AX) with a Buy and maintains $107 price target.
01-16 18:59
今日重点评级关注:Ascendiant Capital:维持GRI Bio"买入"评级,目标价从35美元升至36美元;Ascendiant Capital:维持Atossa Therapeutics"买入"评级,目标价从7.75美元升至8美元
2025-12-09 10:32
DA Davidson analyst Gary Tenner maintains Axos Financial (NYSE:AX) with a Buy and raises the price target from $106 to $107.5.
2025-12-09 02:14
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Axos Financial业绩会实录,以下是2026财年第一季度(截至2025年9月30日)的业绩回顾摘要: ## 1. 财务业绩 **净利息收入**:第一季度净利息收入为2.91亿美元,环比增长1100万美元,年化增长率15.6%。剔除上年同期FDIC贷款预付的1700万美元一次性收益后,同比增长1600万美元,增幅5.8%。 **净利润**:净利润约1.124亿美元,环比增长170万美元(从上季度的1.107亿美元增长)。调整后净利润为1.19亿美元,环比增长7.3%,同比增长近30%。 **每股收益**:稀释每股收益为1.94美元,环比增
2025-12-01 12:27
今日重点评级关注:康托·菲茨杰拉德:维持Cabaletta Bio"超配"评级,目标价从15美元升至30美元;HC Wainwright & Co.:维持Invivyd"买入"评级,目标价从5美元升至10美元
2025-11-03 20:20
Needham analyst Kyle Peterson maintains Axos Financial (NYSE:AX) with a Buy and raises the price target from $105 to $107.
2025-10-31 19:14
Axos Financial (NYSE:AX) reported quarterly earnings of $2.07 per share which beat the analyst consensus estimate of $1.88 by 10.28 percent. This is a 5.61 percent increase over earnings of $1.96 per share from the same
2025-10-31 04:09
The KBW Nasdaq Regional Banking Index (KRX) sank 5.7% in Thursday afternoon trading, its biggest drop since April, following the disclosures by two banks of irregularities related to some loans. Afte...
2025-10-17 02:16